21 Sep 2023 , 09:20 AM
Aurobindo Pharma said on Wednesday that the US Food and Drug Administration issued a Form 483 with one observation after evaluating its formulation production facility in Andhra Pradesh.
The US Food and Drug Administration (US FDA) inspected APL Healthcare Ltd, a wholly-owned subsidiary of the pharma company, in the Tirupati district of Andhra Pradesh from September 13 to 19, 2023, according to a regulatory filing by the Hyderabad-based drug major.
It was mentioned that at the end of the inspection, a Form 483 was given with one procedural observation.
According to the USFDA, after the completion of an inspection, a Form 483 is sent to the firm’s management if the investigator observes any conditions that may constitute violations of the Food, Drug, and Cosmetic (FD&C) Act and other related Acts.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.